Provided by Tiger Trade Technology Pte. Ltd.

ORUKA THERAPEUTICS INC

107.96
+3.102.96%
Pre-market: 107.960.00000.00%07:24 EDT
Volume:935.78K
Turnover:100.83M
Market Cap:7.15B
PE:-53.34
High:109.52
Open:105.48
Low:103.86
Close:104.86
52wk High:115.52
52wk Low:14.34
Shares:66.21M
Float Shares:56.65M
Volume Ratio:1.11
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0242
EPS(LYR):-1.8483
ROE:-18.23%
ROA:-12.95%
PB:6.43
PE(LYR):-58.41

Loading ...

Oruka Therapeutics (ORKA) Files $1b Shelf As Investors Weigh A Pricey Valuation

Simply Wall St.
·
Yesterday

Oruka Therapeutics Files $1 Billion Mixed Shelf

MT Newswires Live
·
Aug 22

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 15

Oruka Therapeutics SVP Finance Arjun Agarwal Disposes of 9,999 Common Shares Worth $1,067,833.92

Reuters
·
Aug 15

Oruka Therapeutics (ORKA) Has a New Rating from Wedbush

TIPRANKS
·
Aug 12

Analysts Are Bullish on These Healthcare Stocks: Oruka Therapeutics (ORKA), Zura Bio (ZURA)

TIPRANKS
·
Aug 12

Jefferies Keeps Their Buy Rating on Oruka Therapeutics (ORKA)

TIPRANKS
·
Aug 11

Guggenheim Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)

TIPRANKS
·
Aug 11

Oruka Therapeutics Inc : Leerink Partners Raises Target Price to $179 from $162

THOMSON REUTERS
·
Aug 11

Oruka Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

Earnings Flash (ORKA) Oruka Therapeutics Posts Q2 Loss $0.55 a Share, vs. FactSet Est of $0.53 Loss

MT Newswires Live
·
Aug 10

Oruka Therapeutics Inc Q2 Net Income USD -41.206 Million

THOMSON REUTERS
·
Aug 10

Oruka Therapeutics Q2 FY26 Net Loss Widens to $41.2 Million; R&D Expenses Rise to $43.3 Million

Reuters
·
Aug 10

Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 10

Oruka Therapeutics Inc : Leerink Partners Raises Target Price to $162 from $120

THOMSON REUTERS
·
Jul 20

Movement Alert|Oruka Therapeutics Rises 9.43% in Regular Trading, Market Anticipates Key H2 Efficacy Data

Market Focus
·
Jul 17

Oruka Therapeutics CMO Joana Goncalves Disposes of 7,000 Common Shares for $601,227.73

Reuters
·
Jul 16

Oruka Therapeutics SVP Finance Arjun Agarwal Sells USD 840,975 in Common Shares

Reuters
·
Jul 14

13D Filings

Dow Jones
·
Jul 11

Movement Alert|Oruka Therapeutics Rises 6.18% in Regular Trading, UBS Bullish on H2 Clinical Data Catalyst for Lead Psoriasis Drug

Market Focus
·
Jul 08